IP Library Granted Patent US 10,875,900
Granted Patent B2
US 10,875,900 · App. 16/782,544 · Granted Dec 29, 2020

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

Inventors: Tomoya Miyakawa (Tokyo, JP); Masaaki Oka (Yamaguchi, JP); Shoichi Hazama (Yamaguchi, JP); Koji Tamada (Yamaguchi, JP); Keiko Udaka (Kochi, JP)
Assignee: Cytlimic Inc.
C07K14/4748A61K38/00A61K39/00A61K39/0011A61P35/00A61P37/04C07K14/705A61K2039/572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,875,900
App. No.
16/782,544
Granted
Dec 29, 2020
Kind
B2
Abstract

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Claims (8)

1. A peptide comprising 8 or more consecutive amino acid residues but 11 or less amino acid residues of SEQ ID NO: 4.

2. A pharmaceutical composition for treating or preventing cancer, comprising the peptide according to claim 1 .

3. The pharmaceutical composition according to claim 2 , wherein the composition is in the form of a vaccine.

4. The pharmaceutical composition according to claim 3 , wherein the peptide can bind to one or more types of HLA molecules.

5. An immunity inducer, comprising the peptide according to claim 1 .

6. The immunity inducer according to claim 5 , wherein the inducer is for inducing a cytotoxic T cell.

7. The immunity inducer according to claim 6 , wherein the peptide can bind to one or more types of HLA molecules.

8. A method for producing an antigen-presenting cell having CTL-inducing activity, comprising a step of contacting the peptide according to claim 1 with an antigen-presenting cell in vitro.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2023
From: CYTLIMIC INC.
To: NEC CORPORATION
Reel/Frame 062357/0203 →
Priority Claims (1)
JP 2015-046463 · Mar 9, 2015 · national
Continuity (3)
Division 16185734 · Nov 9, 2018
Division 15556694
Related Publication 20200157163A1 · May 21, 2020